EGAGenomicsN/Ahttps://ega-archive.org/datasets/EGAD000010073076EGA dataset EGAD00001007307EGAVasp, VASP, DmelCG15112, ENHANCER OF ATNSI ACTIVITY, MALDIVES, Data Set, MV, MDV., MENA, NDPP1, 462, Maldives, l(2)02029, Enb, enb, ENA, Ena, CG15112, ENA/VASPleukemia, Clinical Study Case, Therapy, Followed By, Molecular Fingerprinting, Complete Exome Sequencings, Complete Exome, acute non lymphoblastic leukemia, Myeloid, B-cell Lymphoma 2 Inhibitor, Exome, BCL2 Inhibitor., case, AML, Exome Sequencing, acute non lymphoblastic leukaemia, CASE, Whole Transcriptome, Transcriptome Sequencing, acute myeloid, aml1-evi-1, Next, cbfa2, evi-1, Runx-1, aml, treatment, Acute myelogenous leukemia, WES, Complete Transcriptome, Complete, Leukemia, Complete Transcriptome Sequencing, Exome Sequencings, Myeloblastic, Xaml1, Complete Exome Sequencing, Acute Myeloblastic Leukemia, Whole Transcriptome Sequencing, susceptibility to, Case, Acute Myeloid Leukemia, amlcr1, pebp2ab, aml1, Treatments, Sequencing, Case Dosing Unit, XAML, True Case Status, Packaging Case, Whole Exome, Acute, Following, Therapeutic, Expression Signature, Subsequent, Whole, aml-1, Whole Exome Sequencing, disease management, Therapies, Expression Profiling, Molecular Signature, ANLL, Treatment, Molecular Profiling, Transcriptome Sequencings, BCL-2 Inhibitor, acute myelogenousfalseena-DATASET-WEHI-30-03-2021-00:44:27:049-462 - samplesMolecular profiling by exome sequencing of an AML case following treatment with a BCL2 inhibitor2022-01-11 11:13:47EGAD000010073079606EGAC00001001837EGAS00001004841